- According to Seattle Genetics CEO Eric Dobmeier, the Washington state-based biotech is hiring for 100 positions.
- Seattle Genetics is based in Bothell, WA and develops cancer treatments.
- Overall, Seattle Genetics is preparing for a period of financial investment in order to support full-scale preclinical and clinical development of its product line.
Seattle Genetics is a good example of a biotech company that is growing organically yet aggressively. Much of its effort is directed toward commercialization of its flagship product, Adcetris, which is used to treat lymphoma. While the company took a heavy loss in Q4 2014—$27 million—the market has continued to respond well, with the stock trading steady at around $37.
Seattle Genetics is taking on the entire gambit of activity around R&D, including early-stage development, clinical trial activities and large-scale commercialization. Q1 2015 earnings will be available at some point next week.
And as BioPharma Dive has previously reported, the strength of Adcetris might make Seattle an attractive takeover target for the likes of biotech giants like Gilead.